Vasoactive effects of erythropoietin on human placental blood vessels in vitro

American Journal of Obstetrics and Gynecology

Volumn 188, Issue 4, 2003, Pages 993-996

  Resch, Bela E ^a   Gaspar, Robert ^a   Sonkodi, Sandor ^a   Falkay, George ^a,b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Angiotensin II type 1 receptor; Contractility; Erythropoietin; Human placental blood vessel

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; CAPTOPRIL; LOSARTAN; RECOMBINANT ERYTHROPOIETIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VASOCONSTRICTOR AGENT;

ARTERY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EVALUATION; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; INTRAUTERINE GROWTH RETARDATION; MYOGRAPHY; NORMAL HUMAN; PATHOGENESIS; PLACENTA CIRCULATION; PREECLAMPSIA; PRIORITY JOURNAL; UTERUS CONTRACTION; VEIN; ADULT; DRUG ANTAGONISM; IN VITRO STUDY; PREGNANCY; VASOCONSTRICTION;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIES; CAPTOPRIL; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; LOSARTAN; PLACENTAL CIRCULATION; PREGNANCY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VEINS;

EID: 0038743360     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2003.211     Document Type: Article

References (25)

1. Raine AEG. Hytpertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet 1988;1:97-9.
2. Neff MS, Kim KE, Persoff M, Onesti G, Swartz C. Hemodynamics of uremic anemia. Circulation 1971;43:876-83.
3. Edmunds ME, Walls J. Blood pressure and erythropoietin [letter]. Lancet 1988;1:352.
4. Heidenreich S, Rahn KH, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 1991;39:259-65.
5. Sonkodi S, Resch BE, Letoha A, Ábrahám G, Falkay G. Vasoactive effects of recombinant human erythropoietin (rHuEPO) on the mesenteric artery in normal, hypertensiv and uraemic rats. In vivo and in vitro studies. Am J Hypertens 2001;14:156-7.
6. Eichhorn KH, Bauer C, Eckardt KU, Zimmermann R, Huch A, Huch R. Lack of associations between fetal and maternal serumerythropoietin at birth. Eur J Obstet Gynecol Reprod Biol 1993;50:47-52.
7. Conrad KP, Benyo DF, Westerhausen-Larsen A, Miles TM. Expression of erythropoietin by the human placenta. FASEB J 1996;10:760-8.
8. Dame C, Fahnenstich H, Freitag P, Hofmann D, Abdul-Noir T, Bartmann P, et al. Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood 1998;92:3218-25.
9. Jelkmann W. Biology of erythropoietin. Clin Invest 1994;72:S3-10.
10. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 1994;91:3974-8.
11. Macdougall IC. The role of ACE inhibitors and angiotensinII receptor blockers in the response to epoetin. Nephrol Dial Transplant 1999;14:1836-41.
12. Angus JA, Wright CE. Techniques to study the pharmacodynamics of isolated large and small blood vessels. J Pharmacol Toxicol Meth 2000;44:395-407.
13. Christensen KL, Mulvany MJ. Location of resistance vessels. J Vasc Res 2001;38:1-12.
14. Reilly FD, Russel PT. Neurohistochemical evidence supporting an absence of adrenergic and cholinergic innervation in the human placenta and umbilical cord. Anat Rec 1977;188:277-86.
15. Tanaka C, Kuwabara Y, Sakai T. Structural identification and characterization of arteries and veins in the placental stem villi. Anat Embryol 1999;199:407-18.
16. Fyhrquist F, Rosenlof K, Gronhagen-Riska C, Hortling L, Tikkanen I. Is renin substrate an erythropoietin precursor? Nature 1984;308:649-52.
17. Cooper AC, Robinson G, Vinson GP, Cheung WT, Broughton Pipkin F. The localization and expression of the renin-angiotensin system in the human placenta throughout pregnancy. Placenta 1999;20:467-74.
18. Kingdom JC, McQueen J, Connel JMC, Whittle JM. Fetal angiotensin II levels and vascular (type 1) angiotensin receptors in pregnancies complicated by intrauterine growth retardation. Br J Obstet Gynaecol 1993;100:476-82.
19. Li X, Shams M, Zhu J, Khalig A, Wilkes M, Whittle M, et al. Cellular localization of AT1 receptor mRNA and protein in normal placenta and its reduced expression in intrauterine growth restriction. J Clin Invest 1998;101:442-54.
20. McQueen J, Kingdom JCP, Jardine AG. Vascular angiotensin II and atrial natriuretic peptide receptors in normal and growth-retarded human placentae. J Endocrinol 1990;126:341-7.
21. Wong PC, Chiu AT, Duncia JV, Herblin WF, Smith RD, Timmermans PBMWM. Angiotensin II receptor antagonists and receptor subtypes. Trends Endocrinol Metab 1992;3:211-7.
22. Barrett JD, Zhang Z, Zhu JH, Lee DBN, Ward HJ, Jamgotchian N, at al. Erythropoietin upregulates angiotensin receptors in cultured rat vascular smooth muscle cells. J Hypertens 1998;16:1749-57.
23. Widness JA, Schmidt RL, Sawer ST. Erythropoietin transplacental passage: a review of animal studies. J Perinat Med 1995;23:61-70.
24. Braga J, Marques R, Branco A, Goncalves J, Lobato L, Pimentel JP, et al. Maternal and perinatal implications of the use of human recombinant erythropoietin. Acta Obstet Gynecol Scand 1996;75:449-53.
25. Doering TP, Haller NA, Montgomery MA, Freeman EJ, Hopkins ME The role of AT angiotensin receptor activation in the pathogenesis of preeclampsia. Am J Obstet Gynecol 1998;178:1307-12.